Compass Pathways: Deep Dive Analysis
Compass Pathways plans a Q4 2026 NDA submission for COMP360, a synthetic psilocybin treatment for resistant depression, backed by $466…
NASDAQ
COMPASS Pathways plc
CMPS
1 article
$1.8B Market cap · 2026-09-02
NASDAQ
CMPS
1 article
$1.8B Market cap · 2026-09-02
Compass Pathways plans a Q4 2026 NDA submission for COMP360, a synthetic psilocybin treatment for resistant depression, backed by $466…